Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Cartron

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Bone Marrow Transplantation|April 30, 2002
Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantationJ Domenech, G Cartron, N Clement, et al.
European Journal of Haematology|December 2, 1999
Sezary syndrome in a patient with multiple myeloma: demonstration of a clonally distinct second malignancyG Cartron, P Roingeard, L Benboubker, et al.
Journal of Immunological Methods|July 27, 2007
Evaluation of a peptide ELISA for the detection of rituximab in serumH Blasco, G Lalmanach, E Godat, et al.
Leukemia & Lymphoma|August 28, 1998
CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 casesG Cartron, C Linassier, J L Bremond, et al.
Blood Cancer Journal|January 23, 2016
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groupsA-L Gagez, E Tuaillon, R Cezar, et al.
Blood Cancer Journal|August 22, 2015
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myelomaL Vincent, P Ceballos, C Plassot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2000
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapyC Linassier, C Barin, G Calais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2007
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaF Morschhauser, J F Seymour, H C Kluin-Nelemans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA groupE Tchernonog, P Faurie, P Coppo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centersG Fossard, F Broussais, I Coelho, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|April 30, 2002
Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantationJ Domenech, G Cartron, N Clement, et al.
European Journal of Haematology|December 2, 1999
Sezary syndrome in a patient with multiple myeloma: demonstration of a clonally distinct second malignancyG Cartron, P Roingeard, L Benboubker, et al.
Journal of Immunological Methods|July 27, 2007
Evaluation of a peptide ELISA for the detection of rituximab in serumH Blasco, G Lalmanach, E Godat, et al.
Leukemia & Lymphoma|August 28, 1998
CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 casesG Cartron, C Linassier, J L Bremond, et al.
Blood Cancer Journal|January 23, 2016
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groupsA-L Gagez, E Tuaillon, R Cezar, et al.
Blood Cancer Journal|August 22, 2015
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myelomaL Vincent, P Ceballos, C Plassot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2000
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapyC Linassier, C Barin, G Calais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2007
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaF Morschhauser, J F Seymour, H C Kluin-Nelemans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA groupE Tchernonog, P Faurie, P Coppo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centersG Fossard, F Broussais, I Coelho, et al.
Pageof 4